What novel therapies are under investigation for the treatment of high-risk #MPN ?

Check out our expert video interview with Prithviraj Bose during #ESHMPN2024 to learn more: loom.ly/K5-dT9A
#MPN sm #ESHCONFERENCES #MedicalEducation #MPN Research

Can the addition of parsaclisib after suboptimal ruxolitinib response improve symptoms and reduce splenomegaly in patients with #MF ?
Click here to read more: loom.ly/Hl0txhw

#mpnsm #MedicalEducation

How does MPN impact patient QoL? We summarize a recent publication investigating the physical, psychological, and social impacts of MPN. Read more here loom.ly/PcHKHDU

#mpnsm #MedicalEducation

Our recent #ClinicalTrialClub ended with a dynamic Q&A session, where Angela Fleischman and J.J. Kiladjian answered questions from the audience on treatment sequencing for anemic #myelofibrosis .

Catch up here 👉 loom.ly/8heEYEk

#MPN #MPN sm #MedicalEducation Angela Fleischman

Could fedratinib be the best available treatment in patients with #MF previously treated with ruxolitinib?

Read our article summarizing the latest data from the phase III FREEDOM2 trial 👉 loom.ly/bVTQRKA

#mpnsm #MedicalEducation

How do treosulfan-based conditioning regimens compare to busulfan-based conditioning regimens in patients with MF who will undergo allo-HSCT? Read more here loom.ly/RvL6lKI
#mpnsm #MedicalEducation

What is the incidence of low adherence to ruxolitinib and associated factors in patients with MF or PV?

Read our summary of a prospective study to learn more: loom.ly/MqyGe_k

#MPN #MPN sm #MedicalEducation

If a matched donor is not available for an allo-HSCT in patients with #MF , what is the next best alternative transplant option? Find out more here: loom.ly/-nv40TI
#mpnsm #MedicalEducation

Our recent #ClinicalTrialClub ended with a dynamic Q&A session, where Angela Fleischman and J.J. Kiladjian answered questions from the audience on treatment sequencing for anemic #myelofibrosis .

Watch here 👉 loom.ly/uB2RgWM

#MPN #MPN sm #CancerAwareness Angela Fleischman

We hope you enjoyed following our live updates and congress coverage from  #EBMT 24 !

Keep an eye on our socials for post-congress key points and insights.

#IME   #CancerResearch   #EBMT

In a retrospective comparison with the general population, women with MPN were found to have a 22% decreased childbirth rate.

Read our latest article to learn more about childbirth rates in women with #MPN
loom.ly/PIWBkrk
#MPN sm

CONGRESS #EBMT24 | Nico Gagelmann University Medical Center Hamburg discusses using splenic irradiation prior to allo-HCT to reduce risk of relapse in MF. Splenic irradiation resulted in sig spleen size reduction in 97% of pts, with a median decrease of 5 cm. Splenic irradiation…

CONGRESS #EBMT24 | Nico Gagelmann University Medical Center Hamburg discusses how mut clearance and disease burden could predict relapse after SCT in MF. Mut clearance at day 30 after SCT was predictive of post-SCT relapse at 1 year (P= 0.009). The 6-year DFS was 76% for pts with…

CONGRESS #EBMT24 | Kristin Rathje University Medical Center Hamburg-Eppendorf discusses the impact of ATG/ATLG on outcomes after allo-HCT in MF. The 5-year CIR was 14% vs. 13% and the 5-year CI of death without relapse for both groups was 28%. 5-year OS was similar, at 63% vs…

CONGRESS #EBMT24 | Tatiana Fernández-Barge, Hospital Universitario Marqués de Valdecilla discssuses outcomes of allo-HCT in MF from a mutlicenter cohort. OS at 1 and 5 years was 66.6% and 51.0%. TRM at day 100 was 21.0% and at 1 year was 31.8%. #MPN #MPN sm #medicalcongress

CONGRESS #EBMT24 | Tomasz Czerw, Maria Sklodowska-Curie Institute discusses association between stem cell source, CD34+ dose and outcomes after haplo transplant. For stem cell source, there was no sig difference in OS, PFS, RI, NRM and GVHD. But borderline effect between source…